CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
3BNC117 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02588586
NCT02588586Phase 2Completed
CompareCT.gov

An Open Label, Phase 2 Study of the Safety and Antiretroviral Activity of 3BNC117 in HIV-Infected Individuals on Combination Antiretroviral Therapy

Rockefeller University·interventional·Posted Oct 28, 2015·Updated Jun 16, 2021

In Brief

A Phase 2 clinical trial evaluating 3BNC117 and Antiretroviral Treatment Interruption for HIV-1 Infection. Completed, enrolled 17 participants across 2 sites.

Detailed Summary

This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of antiretroviral therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID), Bill and Melinda Gates Foundation, Weill Medical College of Cornell University, Montefiore Medical Center

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 28, 2015
Enrollment StartOct 1, 2015
Primary CompletionFeb 1, 2018
Study CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.7 years ago

Interventions

3BNC117drug

3BNC117 infusions

Antiretroviral Treatment Interruptionother

Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.